• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Potential Benefit of Rituximab in Rhupus Patients From a Single-Center: A Series of 16 Cases
Conclusions In rhupus refractory to conventional treatment, T or B lymphocytes targeted therapies, and particularly rituximab, seem to be a relevant therapeutic option unlike anticytokine biologics.
Source: JCR: Journal of Clinical Rheumatology - November 24, 2022 Category: Rheumatology Tags: Concise Report Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA. PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - August 18, 2020 Category: Rheumatology Tags: J Rheumatol Source Type: research

Biological agents reduce cardiovascular events in rheumatoid arthritis non-responsive to tumor necrosis factor-inhibitors – a national cohort study
ConclusionsRA TNFi non-responder patients who received second line tocilizumab or abatacept had more benefit on CV events prevention compared with rituximab.
Source: Canadian Journal of Cardiology - January 16, 2020 Category: Cardiology Source Type: research

Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease.
CONCLUSION: In this large cohort of publicly or privately insured patients with RA in the United States, ABA was associated with a 20% reduced risk of CVD versus TNFi. While this observational study is subject to potential residual confounding, our results were consistent in patients with baseline CVD. PMID: 29764964 [PubMed - as supplied by publisher]
Source: J Rheumatol - May 15, 2018 Category: Rheumatology Authors: Jin Y, Kang EH, Brill G, Desai RJ, Kim SC Tags: J Rheumatol Source Type: research

Cardiovascular Safety of Tocilizumab versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis – a Multi‐database Cohort Study
Conclusion: This multi‐database population‐based cohort study found no evidence of an increased CV risk among RA patients who switched from a different biologic drug or tofacitinib to TCZ versus to a TNFi. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - February 27, 2017 Category: Rheumatology Authors: Seoyoung C. Kim, Daniel H. Solomon, James R. Rogers, Sara Gale, Micki Klearman, Khaled Sarsour, Sebastian Schneeweiss Tags: Full Length Source Type: research